celecoxib has been researched along with cimetidine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S | 1 |
| Ayalasomayajula, S; Bizot, MN; Dieterich, HA; Dole, WP; Howard, D; Tchaloyan, S; Yeh, CM | 1 |
| Akiba, Y; Amagase, K; Ebara, S; Satoh, H; Takeuchi, K | 1 |
| Baek, JS; Lee, YH; Loo, SCJ; Tan, NS; Yeo, EW | 1 |
| Be Rziņš, KR; Fraser-Miller, SJ; Gordon, KC; Rades, T | 1 |
| Fukuma, Y; Iwamoto, T; Kobayashi, T; Kushima, Y; Matsumoto, M; Miyamoto, T; Nakamura, M; Sato, Y | 1 |
2 review(s) available for celecoxib and cimetidine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for celecoxib and cimetidine
| Article | Year |
|---|---|
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amides; Atenolol; Celecoxib; Cimetidine; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Drug Interactions; Enzyme Inhibitors; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Pyrazoles; Renin; Sulfonamides | 2005 |
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Topics: Adolescent; Adult; Allopurinol; Amides; Antihypertensive Agents; Celecoxib; Cimetidine; Cyclooxygenase Inhibitors; Drug Interactions; Female; Fumarates; Gout Suppressants; Histamine H2 Antagonists; Humans; Hypertension; Male; Middle Aged; Pyrazoles; Reference Values; Renin; Sulfonamides | 2008 |
10 other study(ies) available for celecoxib and cimetidine
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats.
Topics: Animals; Blotting, Western; Cats; Celecoxib; Cimetidine; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diet; Dinoprostone; Duodenal Diseases; Duodenum; Female; Histamine H2 Antagonists; Immunohistochemistry; Intestinal Mucosa; Male; Pyrazoles; Sulfonamides | 2013 |
Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Capsules; Celecoxib; Cimetidine; Delayed-Action Preparations; Diffusion; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Gastric Juice; Histamine H2 Antagonists; Ibuprofen; Inflammation; Kinetics; Models, Chemical; Nanocapsules; Nanotechnology; Naproxen; Polymers; Solubility; Technology, Pharmaceutical | 2017 |
Low-Frequency Raman Spectroscopy as an Avenue to Determine the Transition Temperature of β- and γ-Relaxation in Pharmaceutical Glasses.
Topics: Calorimetry, Differential Scanning; Celecoxib; Cimetidine; Indoles; Pharmaceutical Preparations; Phenylcarbamates; Sensitivity and Specificity; Spectrum Analysis, Raman; Sulfonamides; Temperature; Transition Temperature; Valsartan | 2022 |
TNFα-dependent mTOR activity is required for tenotomy-induced ectopic ossification in mice.
Topics: Achilles Tendon; Activities of Daily Living; Animals; Celecoxib; Cimetidine; Female; Humans; Male; Mice; Ossification, Heterotopic; Tenotomy; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2023 |